血清肿瘤标志物五项联合检测在肺癌诊断中的临床应用

Clinical application of five serum tumor markers combined tests in the diagnosis of lung cancer

目的:分析肺癌诊断过程中血清肿瘤标志物联合检测的临床价值。方法:选取肺癌患者61例,作为肺癌组;肺部良性病变患者66例,作为良性病变组;另选择体检健康者51例,作为对照组。比较三组血清中肿瘤标志物检测五项结果。结果:肺癌组血清中血清癌胚抗原(CEA)、细胞角蛋白19片段(CYFRA21-1)、神经元特异性烯醇化酶(NSE)、糖类抗原125(CA 125)、胃泌素释放肽前体(ProGRP)均显著高于肺部良性病变组及对照组,差异有统计学意义(P<0.05)。肺癌诊断中联合检测肿瘤标志物五项,以CEA+CA 125+CYFRA21-1+NSE+ProGRP阳性率最高,显著优于CEA+NSE+CYFRA21,差异有统计学意义(P<0.05)。结论:在肺癌诊断过程中联合检测血清肿瘤标志物五项,可获得较高阳性率,具有重要临床应用价值。

Objective:To analyze the clinical value of combined detection of serum tumor markers in the diagnosis of lung cancer.Methods:61 patients with lung cancer were selected as the lung cancer group.66 patients with benign pulmonary lesions were selected as the benign lesion group.Another 51 cases with health examination were selected as the control group.Five results of tumor markers detection in serum of the three groups were compared.Results:Serum carcinoembryonic antigen(CEA),Cytokeratin 19 fragment(CYFRA21-1),Neuron-specific enolase(NSE),Carbohydrate antigen 125(CA 125),and Progenitor of gastrin releasing peptide(ProGRP)of the serum in lung cancer group are all significantly higher than the benign lung lesions group and control group,with the differences were statistically significant(P<0.05).Five serum tumor markers combined tests in the diagnosis of lung cancer,the positive rate of CEA+CA 125+CYFRA21-1+NSE+ProGRP was the highest,which was significantly better than CEA+NSE+CYFRA21,with the differences were statistically significant(P<0.05).Conclusion:Five serum tumor markers were combined tested during the diagnosis of lung cancer,can be obtain higher positive rate,which has important clinical application value.